Drug acquisition

Search documents
Verona Pharma Stock Jumps 20% on $10B Buyout Offer From Merck
ZACKSยท 2025-07-09 14:20
Key Takeaways Merck will acquire VRNA for $107 per ADS in a $10B deal, adding Ohtuvayre to its portfolio. Ohtuvayre is FDA-approved for COPD and being studied for bronchiectasis, CF, and asthma. The acquisition supports Merck's shift away from Keytruda dependence ahead of its 2028 LOE.Verona Pharma (VRNA) has signed a definitive agreement with pharma bigwig Merck (MRK) . Per the terms, the pharma giant will acquire all outstanding shares of VRNA for $107 per American depositary share (ADS), valuing the de ...